within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01C_BetaLactamAntibacterialsPenicillins.J01CA13_Ticarcillin;

model Ticarcillin
  extends Pharmacolibrary.Drugs.ATC.J.J01CA13;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>J01CA13</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Ticarcillin is a broad-spectrum, semi-synthetic penicillin antibiotic primarily used for the treatment of infections caused by susceptible Gram-negative and some Gram-positive bacteria. It is historically used in the management of serious infections such as those due to Pseudomonas aeruginosa. Ticarcillin is often combined with clavulanic acid to overcome beta-lactamase-mediated resistance. It has largely been replaced by other agents in many therapeutic settings, but may still be used in some hospitals.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy adult volunteers following intravenous administration.</p><h4>References</h4><ol><li><p>Dulhunty, JM, et al., &amp; Lipman, J (2015). A Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis. <i>American journal of respiratory and critical care medicine</i> 192(11) 1298–1305. DOI:<a href=\"https://doi.org/10.1164/rccm.201505-0857OC\">10.1164/rccm.201505-0857OC</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26200166/\">https://pubmed.ncbi.nlm.nih.gov/26200166</a></p></li><li><p>Wilson, WD, et al., &amp; Pryor, P (1991). Pharmacokinetics and bioavailability of ticarcillin and clavulanate in foals after intravenous and intramuscular administration. <i>Journal of veterinary pharmacology and therapeutics</i> 14(1) 78–89. DOI:<a href=\"https://doi.org/10.1111/j.1365-2885.1991.tb00807.x\">10.1111/j.1365-2885.1991.tb00807.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2038098/\">https://pubmed.ncbi.nlm.nih.gov/2038098</a></p></li><li><p>Dulhunty, JM, et al., &amp; Lipman, J (2013). Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. <i>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</i> 56(2) 236–244. DOI:<a href=\"https://doi.org/10.1093/cid/cis856\">10.1093/cid/cis856</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23074313/\">https://pubmed.ncbi.nlm.nih.gov/23074313</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Ticarcillin;
